Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.
作者信息
Furqan Fateeha, Watson Grace, Samaniego Felipe, Fayad Luis E, Morrison Michael W, Thompson Philip A, Steiner Raphael E, Chi Linda, Dabaja Bouthaina, Pinnix Chelsea C, Neelapu Sattva S, Nastoupil Loretta J, Strati Paolo
机构信息
Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Leuk Lymphoma. 2020 Dec;61(12):2980-2984. doi: 10.1080/10428194.2020.1791849. Epub 2020 Jul 10.
Abstract
摘要
相似文献
1
Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.以伊布替尼为基础的疗法用于治疗累及中枢神经系统的边缘区淋巴瘤。
Leuk Lymphoma. 2020 Dec;61(12):2980-2984. doi: 10.1080/10428194.2020.1791849. Epub 2020 Jul 10.
2
Ibrutinib-induced spinal haematoma in a patient with marginal zone lymphoma.伊布替尼致边缘区淋巴瘤患者脊髓血肿。
BMJ Case Rep. 2024 Aug 31;17(8):e260598. doi: 10.1136/bcr-2024-260598.
3
Evaluating ibrutinib for the treatment of relapsed/refractory marginal zone lymphoma.评估伊布替尼治疗复发/难治性边缘区淋巴瘤。
Expert Opin Pharmacother. 2021 Sep;22(13):1643-1649. doi: 10.1080/14656566.2021.1941864. Epub 2021 Jun 21.
4
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.伊布替尼治疗复发/难治性边缘区淋巴瘤的预测因素和结局：一项多中心队列研究。
J Hematol Oncol. 2022 Jul 16;15(1):96. doi: 10.1186/s13045-022-01316-1.
5
How should we use ibrutinib in patients with mantle cell lymphoma?我们应该如何在套细胞淋巴瘤患者中使用依鲁替尼？
Br J Haematol. 2021 May;193(3):445-446. doi: 10.1111/bjh.17364. Epub 2021 Mar 10.
6
B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy.B 细胞淋巴瘤患者来源异种移植模型可用于药物发现，也是个性化治疗的平台。
Clin Cancer Res. 2017 Aug 1;23(15):4212-4223. doi: 10.1158/1078-0432.CCR-16-2703. Epub 2017 Mar 27.
7
Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy.伊布替尼联合CIT治疗儿童复发/难治性成熟B细胞非霍奇金淋巴瘤（SPARKLE试验）：初步安全性、药代动力学和疗效
Leukemia. 2020 Aug;34(8):2271-2275. doi: 10.1038/s41375-020-0749-5. Epub 2020 Feb 18.
8
Resistance mechanism for ibrutinib in marginal zone lymphoma.边缘区淋巴瘤中伊布替尼的耐药机制。
Blood Adv. 2019 Feb 26;3(4):500-502. doi: 10.1182/bloodadvances.2018029058.
9
Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies.依鲁替尼治疗后出现的严重溃疡性胃肠道毒性：两项病例研究
Leuk Lymphoma. 2021 Apr;62(4):984-987. doi: 10.1080/10428194.2020.1845333. Epub 2020 Nov 12.
10
Hemorrhagic Cellulitis and Osteomyelitis Secondary to Ibrutinib Therapy.依鲁替尼治疗继发的出血性蜂窝织炎和骨髓炎
Am J Ther. 2021;28(1):e148-e150. doi: 10.1097/MJT.0000000000000979.
引用本文的文献
1
An Unusual Therapy for an Atypical Case of Secondary Extranodal, Non-parenchymal Central Nervous System Marginal Zone Lymphoma.非典型继发性结外非实质中枢神经系统边缘区淋巴瘤的一种特殊治疗方法。
Cureus. 2025 Feb 22;17(2):e79468. doi: 10.7759/cureus.79468. eCollection 2025 Feb.
2
Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?Tp53 功能破坏：慢性淋巴细胞增殖性疾病中是否存在预后不良的标志物？
Blood Res. 2021 Dec 31;56(4):333-334. doi: 10.5045/br.2021.2020322.
本文引用的文献
1
An international multicenter retrospective analysis of patients with extranodal marginal zone lymphoma and histologically confirmed central nervous system and dural involvement.国际多中心回顾性分析伴有结外边缘区淋巴瘤和组织学证实的中枢神经系统及硬脑膜受累的患者。
Cancer Med. 2020 Jan;9(2):663-670. doi: 10.1002/cam4.2732. Epub 2019 Dec 5.
2
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.伊布替尼治疗 Bing-Neel 综合征：一项多中心研究。
Blood. 2019 Jan 24;133(4):299-305. doi: 10.1182/blood-2018-10-879593. Epub 2018 Dec 6.
3
Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis.原发性中枢神经系统淋巴瘤患者的组织学亚型和治疗方式的影响：一项监测、流行病学和最终结果（SEER）数据库分析
Oncotarget. 2018 Jun 22;9(48):28897-28902. doi: 10.18632/oncotarget.25622.
4
Clinical response and pharmacokinetics of bendamustine as a component of salvage R-B(O)AD therapy for the treatment of primary central nervous system lymphoma (PCNSL).在挽救性 R-B(O)AD 治疗中作为组成部分的苯达莫司汀治疗原发性中枢神经系统淋巴瘤（PCNSL）的临床反应和药代动力学。
BMC Cancer. 2018 Jul 9;18(1):729. doi: 10.1186/s12885-018-4632-y.
5
Extranodal Marginal Zone Lymphoma of the Central Nervous System.中枢神经系统结外边缘区淋巴瘤
Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):34-37.e8. doi: 10.1016/j.clml.2017.09.012. Epub 2017 Sep 23.
6
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.依鲁替尼对原发性中枢神经系统淋巴瘤中B细胞受体信号传导的抑制作用
Cancer Cell. 2017 Jun 12;31(6):833-843.e5. doi: 10.1016/j.ccell.2017.04.012. Epub 2017 May 25.
7
Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.在复发/难治性边缘区淋巴瘤中使用依鲁替尼靶向布鲁顿酪氨酸激酶。
Blood. 2017 Apr 20;129(16):2224-2232. doi: 10.1182/blood-2016-10-747345. Epub 2017 Feb 6.
8
Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences.边缘区硬脑膜淋巴瘤：纪念斯隆凯特琳癌症中心和迈阿密大学的经验
Leuk Lymphoma. 2017 Apr;58(4):882-888. doi: 10.1080/10428194.2016.1218006. Epub 2016 Sep 21.
9
Ibrutinib responsive central nervous system involvement in chronic lymphocytic leukemia.依鲁替尼反应性中枢神经系统受累于慢性淋巴细胞白血病。
Blood. 2016 May 12;127(19):2356-8. doi: 10.1182/blood-2016-02-697193. Epub 2016 Mar 18.
10
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
Zotero 插件